

Curriculum Vitae
Claudio Jommi



Professor of Practice
 Government, Health and Not for Profit Division
 SDA Bocconi School of Management
 Via Bocconi 8, 20129 Milano
 Phone +39-02-58362601
 Fax +39-02-58362598
 Mob +39-348-5941094
 E-mail: claudio.jommi@unibocconi.it

PERSONAL INFORMATION	
Name, Surname	Claudio, Jommi
Date and Place of Birth	November 15 th of 1966, Milan
Address	Milan, Via Lambro 4
Nationality	Italian
Mother tongue	Italian
Other languages	English (excellent - written and spoken), Spanish (good)
ACADEMIC POSITION	
Academic Position	<p><i>Current</i> Bocconi University</p> <p>Member of the Executive Committee, Director of the Health Policy Area and Scientific Coordinator of the Pharmaceutical Observatory, CERGAS (Centre for Research on Health and Social Care Management), SDA (School of Management) Bocconi, Milan, Italy</p> <p>Coordinator of the Specialisation in Pharmaceutical and Medical Technologies, Master in Health Management, Economics and Policy, (Mihmep), Public Management and Policy Department, SDA (School of Management), Bocconi</p> <p><i>Past</i> Università del Piemonte Orientale</p> <p>Associate Professor of Management, Università degli Studi del Piemonte Orientale, Department of Pharmaceutical Sciences, Novara, Italy</p>

	<p>Member of Scientific Board of the Master di secondo livello in Discipline Regolatorie e Market Access in Ambito Farmaceutico-Biotecnologico, Università del Piemonte Orientale</p> <p>Member of the Scientific Committee of the Centro di Eccellenza Interfacoltà di Servizi per il Management Sanitario, CEIMS, Università del Piemonte Orientale</p> <p>Member of the Patent Committee, Università del Piemonte Orientale</p>
TEACHING	
Main teaching activities	<p><u>Undergraduate courses</u></p> <p>Novara</p> <ul style="list-style-type: none"> • Management of Pharmacy and Pharmacoeconomics (taught in Italian, since 2007) (Pharmacy, 72 hours) • Intellectual Property Rights and Technology Transfer (taught in Italian, since 2007) (Biotechnology, 40 hours) • Economics and Management of Pharmaceuticals (taught in Italian, since 2007) (Biotechnology 2007-2012; CTF - Chimica e Tecnologia Farmaceutiche, since 2015, 56 hours) <p><u>Postgraduate courses</u></p> <p>SDA Bocconi</p> <ul style="list-style-type: none"> • Health Economics (Mihmep, taught in English, since 2000) • Pharmaceutical Policy and Management (Mihmep, taught in English, since 2000). • Regulation, entrepreneurship and management in the Biotech Sector (Mihmep, taught in English, 2005-2010) • Executive courses in HTA and Market Access (taught in Italian and English, since 2000) <p>Novara</p> <ul style="list-style-type: none"> • Master of Regulatory Affairs and Market Access (taught in Italian, since 2011) • Scuola di Specializzazione in Farmacia Ospedaliera (taught in Italian, since 2012)
RESEARCH	
Research Interests	<p>Pharmaceutical economics, policy and management</p> <p>Policy impact analysis</p> <p>Health care systems analysis</p> <p>HTA and Economic evaluation of health care programmes</p>
Main recent research projects (since 2010)	<p><u>CERGAS SDA Bocconi</u></p> <ul style="list-style-type: none"> • Costs of PCSK9 therapeutic pathways (sponsored by Amgen) (2019) • Regulation of community pharmacies across Europe and effects of liberalisation (sponsored by WBA) (2019) • Nutrition policy and management (sponsored by Aiipa, Italian Association of Food Products, Health Unit, 2018) • Clinical research for drugs: cost avoidance and management issue (Novartis Academy) (Sponsored by Novartis, 2015-2016) • Budget Impact Analysis of rituximab biosimilar (sponsored by Sandoz) • Prioritisation criteria of vaccination programme (sponsored by SK Foundation) (2016-2017) • Systematic review of costs of influenza (sponsored by Angelini)

	<p>(2016)</p> <ul style="list-style-type: none"> • Pharmaceutical Observatory, since 2000 (sponsored by Abbvie, AstraZeneca, Bayer, Biogen, Boheringer I., Celgene, Janssen-Cilag, Merck Sharp and Dhome, Novartis, Pfizer, Roche, Sanofi, Takeda, Teva) • The assessment of COPD drugs by payers: a Delphi Study, 2013-2014 (sponsored by GSK) • Procurement policies for Medical Gas, 2013 (sponsored by Assogastecnici) • The costs of self-sufficiency for plasma and blood derivatives, 2011-2012 (sponsored by Baxter, Biotest, CSL Behring, Grifols and Octopharma) • The impact of reference pricing for drugs in Italy, 2010 (sponsored by Menarini) • 2020 Vision for Rheumatoid Arthritis Research, 2010-2011 (sponsored by Roche Basel) • Management of clinical research for medical devices, 2011-2012 (research fund, Department of Health) • Different projects on OTC Drugs and Self-Medication, since 2003 (sponsored by Assosalute, Associazione Nazionale Industria Farmaceutica di Automedicazione) <p><u>Novara</u></p> <ul style="list-style-type: none"> • Administration costs of parenteral cancer drugs (sponsored by Piedmont Region) (2018) • MCDA for obinutuzumab (sponsored by Roche) (2018) • Delphi Study on the costs of adverse events from infusion of drugs and budget impact analysis for colorectal cancer (sponsored by Amgen) (2016) • Delphi Study on market access issues for immunotherapies (sponsored by BMS) (2015) • Research Centre on Red Biotechnologies and the Biotech Industry (with Cergas Bocconi) (2012-2015) (sponsored by Assobiotec) • Budget Impact Analysis of Signifor and Jakavi, 2013-2014 (sponsored by Novartis) • Forecasting model for drug utilization and expenditure integrating a Cellular Automata model with the Budget Impact Analysis approach, 2012-2014 (with the Italian Horizon Scanning Project, Università degli Studi di Padova and Cineca) (research fund Ministero della Salute – Direzione Generale della Ricerca Scientifica e Tecnologica 2011-2014) • Estimating costs of Multiple Sclerosis through an administrative database (sponsored by Novartis) (2012) • Delphi Study on the perspective use of economic evaluation and budget impact analysis in the Italian NHS, 2011 (sponsored by AstraZeneca) • Regional and local formularies in the Italian NHS, 2010-2012 (sponsored by Eli-Lilly) • Prospective study on the costs of renal chronic failure, 2010-2014 (sponsored by Abbott/Abbvie)
INTERNATIONAL ACTIVITIES	
International Activities (projects, teaching)	<p>University Claude Bernard Lyon 1</p> <ul style="list-style-type: none"> • Short Visiting Professor, “European Market Access University Diploma”, “Pharmaceutical policy in Italy” (since 2010) <p>Health Economics Unit, School of Health and Population Sciences, University of Birmingham (2011) “The impact of reference pricing in Italy”</p>

	<p>Essec Sanofi-Aventis Chair in Biotechics and Drug Innovation, Essec Business School, Cergy (Paris), France</p> <ul style="list-style-type: none"> • Guest Speaker, Postgraduate Programme “Health economics”, “Regionalisation of health policy in the Italian NHS and impact on the industry (2007) • Guest Speaker, Postgraduate Programme “Drug Innovation Management”, “Public-private partnerships in drug development” (2006) <p>St Joseph University, Philadelphia, USA</p> <ul style="list-style-type: none"> • Guest Speaker, at “Pharmaceutical Marketing MBA Programme”, della Herivan K. Haub School of Business, St Joseph University, “Pharmaceutical policy and management in the Western EU Countries” (2004) <p>Visiting Research Scholar at the Department of Health and Social Care, London School of Economics (June – September 2000)</p>
MAIN PUBLICATION	
Main articles in peer-reviewed journals (from 2013)	<p>Cavazza M, Banks H, Muscaritoli M, Rondanelli MA, Zandonà E, Jommi C. Patient access to oral nutritional supplements: which policies count? Nutrition. Available online 23 July 2019, 110560. In Press, Journal Pre-proof (https://doi.org/10.1016/j.nut.2019.110560).</p> <p>Villa F, Tutone M, Altamura G, Antignani S, Cangini A, Fortino I, Melazzini M, Trotta F, Tafuri G, Jommi C. Determinants of price negotiations for new drugs. The experience of the Italian Medicine Agency. Health Policy 2019. 123(6):595-600</p> <p>Otto MH, Pillarella C, Jommi C, The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy. Front Pharmacol. 2018; 9: 1069.</p> <p>Federici C, Cavazza M, Costa F, Jommi C, Health care costs of influenza-related episodes in high income countries: A systematic review. PLoS One. 2018;13(9):e0202787.</p> <p>Jommi C, Bertolani A, Patients’ Associations and HTA for medicines: actual and future role in Italy, GRHTA (Global & Regional Health Technology Assessment) 2018:1-11.</p> <p>Otto M, Patrizio A, Jommi C, Variations in non-prescription drug consumption and expenditure: determinants and policy implications, Health Policy 2018; 122(6):614-620.</p> <p>Espin J, Schlander M, Godman B, Anderson P, Mestre-Ferrandiz J, Borget I, Hutchings A, Flostrand S, Parnaby A, Jommi C. Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates. Appl Health Econ Health Policy 201; 16(6):803-817.</p> <p>Lidonnici D, Ronco V, Isernia M, Lanati E, Jommi C, Canonico PL, Genazzani A . Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: Analisi delle tempistiche di valutazione dell’Agenzia Italiana del Farmaco. GRHTA (Global & Regional Health Technology Assessment) 2018:1-9.</p> <p>Cozzolino M, Bolasco P, Ronco C, Conte G, Menè P, Mereu MC, Di Luca M, Roccatello D, Rosati A, Jommi C, Costanzo AM, Gualberti G, di Luzio Paparatti U, Remuzzi G, Clinical Management of Chronic</p>

Kidney Disease Patients in Italy: Results from the IRIDE Study. *Nephron*. 2018;140(1):39-47.

Jommi C, Armeni P, Battista M, di Procolo P, Conte G, Ronco C, Cozzolino M, Costanzo AM, di Luzio Papparatti U, Concas G, Remuzzi G. The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study, *Pharmacoecoon Open*. 2018;2(4):459-467.

Villa F, **Jommi C**, Genazzani A, Antignani S, Montilla S, Melazzini M. Accesso precoce al mercato: dalle approvazioni condizionate di EMA agli accordi negoziali particolari di AIFA. *GRHTA (Global & Regional Health Technology Assessment 2018)*: 1–10.

Callea G, Armeni P, Marsilio M, **Jommi C**, Tarricone R, The impact of HTA and procurement practices on the selection and prices of medical devices. *Soc Sci Med*. 2017;174:89-95.

Nayroles G, Frybourg S, Gabriel S, Kornfeld Å, Antoñanzas-Villar F, Espín J, **Jommi C**, Martini N, de Pouvourville G, Tolley K, Wasem J, Toumi M, Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. *J Mark Access Health Policy* 2017: 12;5(1):1298190.

Perrone F, **Jommi C**, Di Maio M, Gimigliano A, Gridelli C, Pignata S, Ciardiello F, Nuzzo F, de Matteis A, Del Mastro L, Bryce J, Daniele G, Morabito A, Piccirillo MC, Rocco G, Guizzaro L, Gallo C, The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. *Ann Oncol*. 2016: 27 (12): 2224-2229.

Sommariva S, Finch AP, **Jommi C**, The assessment of new drugs for asthma and COPD: a Delphi study examining the perspectives of Italian payers and clinicians. *Multidiscip Respir Med*. 2016 Jan;27:11:4.

Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E, Gerkens S, Henschke C, Hislop J, **Jommi C**, Kaitelidou D, Kawalec P, Keskimaki I, Kroneman M, Lopez Bastida J, Pita Barros P, Ramsberg J, Schneider P, Spillane S, Vogler S, Vuorenkoski L, Wallach Kildemoes H, Wouters O, Busse R. Pharmaceutical regulation in 15 European countries review. *Health Syst Transit*. 2016 Oct;18(5):1-122.

Ciani O, Armeni P, Boscolo PR, Cavazza M, **Jommi C**, Tarricone R. De innovazione: The concept of innovation for medical technologies and its implications for healthcare policy-making. *Health Policy and Technology* 2016;5(1):47-64.

Finch AP, Dritsaki M, **Jommi C**., Generic Preference Based Measures for Low Back Pain: Which of Them Should Be Used? *Spine* 2016;41(6):E364-74.

Armeni P, **Jommi C**, Otto M. The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study, *Eur J Health Econ* 2016;17(8):963-977.

Jommi C, Mennini F, Canonico PL, Bruzzi P, Immuno-therapy in the treatment of cancer: implications for efficacy and economic evaluations *GRHTA (Global & Regional Health Technology Assessment) 2016*; 3(1):1-8.

Jommi C. Innovation and drugs price and reimbursement: a

	<p>comparison between Italy and the other major EU countries. GRHTA (Global and Regional Health Technology Assessment) 2015;2(3):117-162.</p> <p>Costa F, Armeni P, Otto MH, Amoroso N, Jommi C. La rendicontazione e la remunerazione dei farmaci. Finalità, struttura e gestione del File F in nove Regioni italiane. Mecosan 2016; 98: 61-82.</p> <p>Sommariva S, Cavazza M, Compagni A, Jommi C. I registri in sanità e la creazione di conoscenza: dai database alla produzione scientifica. Politiche sanitarie 2015;16(3):168-176.</p> <p>Jommi C, Bianco A, Chiumente M, et al. Il costo della distribuzione diretta dei farmaci in dieci aziende sanitarie piemontesi. Giornale Italiano di Farmacia Clinica 2015;29(3):152-169.</p> <p>Gehring M, Jommi C, Tarricone T, et al. Towards a More Competitive Italy in Clinical Research: The Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). Epidemiology, Biostatistics and Public Health 2015;12(1):e10246-1/9.</p> <p>Ciani O, Jommi C, The role of health technology assessment bodies in shaping drug development. Drug Des Devel Ther 2014;8:2273-81.</p> <p>Costa E, Biasi V, Concia E, Jommi C, Lattuada E; Manfrè S; Venturini F; Lanzafame M. La riduzione del dosaggio giornaliero di efavirenz nella terapia antiretrovirale: impatto sul budget nell'azienda ospedaliera universitaria integrata di Verona. Le Infezioni in Medicina 2014, 2:118-123.</p> <p>Di Procolo P, Jommi C. Current pipelines for neglected diseases. PLoS Negl Trop Dis. 2014;8(9):e3092.</p> <p>Cargnin S, Jommi C, Canonico PL et al (2014), Diagnostic accuracy of HLA-B*5701 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review. Pharmacogenomics 2014;15(7):963-76.</p> <p>Callea G, Armeni P, Tarricone R, Cavazza M, Jommi C. The Determinants of Uptake and Diffusion of Innovative Health Technologies. An Empirical Analysis, Value Health. 2014 Nov;17(7):A501.</p> <p>Jommi C, Dellamano L, Valutazione del beneficio incrementale e prezzo di cessione per i farmaci rimborsati: il caso dell'AMNOG tedesco Pharmacoeconomics Italian Research Articles 2013;15(Suppl.):25-33.</p> <p>Jommi C, Costa E, Michelon A, et al. Multi-tier drugs assessment in a decentralised health care system. The Italian case-study, Health Policy 2013; 112(3):241-247.</p> <p>Toumi M, Zard J, Duvillard R, Jommi C. Innovative medicines and market access agreements, Ann Pharm Fr. 2013;71(5):302-25.</p> <p>Jommi C, Costa F. I prezzi a ricavo industria dei farmaci rimborsabili: l'Italia a confronto con i principali paesi Ue, Politiche Sanitarie 2013;14(2):1-12.</p> <p>Ghislandi S, Armeni P, Jommi C 2013, The impact of generic reference pricing in Italy, a decade on. Eur J Health Econ.14(6), 959-69</p>
--	--


	<p>Jommi C, Iorio A, Crippa L et al (2013), Analisi di impatto sul budget di Watchman™, dispositivo per la prevenzione tromboembolica nei pazienti con fibrillazione atriale, <i>Pharmacoeconomics Italian Research Articles</i>, 15, 45-3</p>
Books and Chapters in Books	<p><u>Books</u> (since 2001)</p> <p>Cavazza M, Costa F, Jommi C (2016). <i>Organizzazione e gestione delle sperimentazioni cliniche</i>. Egea, Milano, 2016.</p> <p>Cavazza M, Jommi C (2013). <i>La raccolta di plasma ed il sistema di emocomponenti ed emoderivati in Italia</i>. Egea, Milano, 2013.</p> <p>Jommi C. (editor) (2004), <i>Il sistema di finanziamento delle aziende sanitarie pubbliche</i>, Milano, Egea, 2004.</p> <p>Jommi C. (2001), <i>Pharmaceutical policy and organisation of the regulatory authorities in the main EU countries</i>, EGEA, Milano.</p> <p><u>Chapters in books</u> (since 2007)</p> <p>Costa F, Jommi C (2018), Le principali politiche del farmaco in Italia, in Ferrari GF (a cura di). <i>Osservatorio del Farmaco 2018</i>. Milano, Egea.</p> <p>P, Bertolani A, Costa F, Otto M. Jommi C. L'acquisto di farmaci in Italia: l'effetto di approcci selettivi. In <i>Rapporto OASI 2018</i>, Egea, Milano, pp. 611-647.</p> <p>Jommi C (2018). <i>Managed Entry Agreements and High Cost Medicines (European Perspective)</i>, in Zaheer-Ud-Din Babar (ed.). <i>Equitable Access to High-Cost Pharmaceuticals</i>, Springer, London, 2018.</p> <p>Armeni P, Bertolani A, Costa F, Jommi C, Otto M (2017), <i>Politiche del farmaco ed impatto sulla spesa: gli effetti di quindici anni di decentramento nel SSN</i>, in AAVV (a cura di), <i>Rapporto OASI 2017</i>, Egea, Milano.</p> <p>Toumi M, Zard J, Abdallah IB, Jommi C, Cohen J (2017). <i>An overview of Market Access Agreements</i>. in Ethgen O, Staginnus O (ed), <i>The future of Health Economics</i>. Routledge, 75-108.</p> <p>Jommi C, (2017). <i>An Introduction to Economic Evaluation of Health Care Programs</i>, Zaheer-Ud-Din Babar (ed.). <i>Economic evaluation of pharmacy services</i>. Academic Press, London, pp. 1-9.</p> <p>Jommi C, Minghetti P (2015). <i>Pharmaceutical Pricing Policies in Italy</i>, in (Zaheer-Ud-Din Babar (ed.), <i>Pharmaceutical Prices in the 21st Century</i>, Springer, London, pp. 131-151</p> <p>Amoroso N. Armeni P, Costa F, Jommi C, Otto M, (2016). <i>Il governo dell'assistenza farmaceutica in Italia: possibili traiettorie di cambiamento in AAVV</i> (a cura di) <i>Rapporto OASI 2016</i>.</p> <p>Cavazza M, Costa F, Jommi C (2014). <i>La ricerca clinica in nove ospedali italiani: organizzazione e analisi di percezione</i>, in AAVV, <i>Rapporto Oasi 2014</i>, Egea, Milano, pp. 463-492</p> <p>Jommi C, Di Procolo P, Drago V (2013). "Education and research on drug market access in low-income countries: the experience of the</p>

	<p>Department of Pharmaceutical Sciences in Novara", in Missoni E, Tedioli F (Ed), Education in Global Health Policy and Management, Egea, Milano, 129-151.</p> <p>Armeni P, Cavazza M, Jommi C (2012). L'attività sperimentale sui dispositivi medici, in Tarricone R, Politiche per la salute e scelte aziendali. Impatto sull'innovazione e diffusione delle tecnologie mediche, Egea, Milano, 2012, 237-264.</p> <p>Jommi C, Armeni P, De Luca C, Otto M, Vella V (2012). Il governo regionale dell'assistenza farmaceutica e il suo impatto sulla spesa, Cantù E (a cura di), Rapporto OASI 2011, Egea, Milano.</p> <p>Jommi C (2011). Value Based Pricing per i farmaci, in De Vincenti C., Finocchi Ghersi, A., Tardiola, A., La Sanità in Italia, Organizzazione, governo, regolazione, mercato. Il Mulino, Bologna.</p> <p>Jommi C, Cavazza M (2009). Le organizzazioni di HTA in Europa. in Anessi Pessina E., Cantù E. (a cura di), Rapporto OASI 2009.</p> <p>Jommi C, Aguzzi G, Otto M (2008). Il confronto internazionale tra prezzi dei farmaci: aspetti metodologici, principali risultati in letteratura e studio sui farmaci con obbligo di prescrizione. In: Giorgio Macciotta. La Salute e il mercato. La ricerca farmaceutica tra Stato, industria e cittadini, 19-47, Il Sole 24 Ore, Milano.</p> <p>Jommi C, Lecci F (2008) "La spesa sanitaria: composizione ed evoluzione", in Anessi Pessina E., Cantù E. (a cura di), Rapporto OASI 2008. L'aziendalizzazione della sanità in Italia. 95-150, Milano, Egea, 2008.</p> <p>Cavalli L, Jommi C., Lecci F., "La spesa sanitaria: composizione ed evoluzione", in Anessi Pessina E., Cantù E. (a cura di), Rapporto OASI 2007. L'aziendalizzazione della sanità in Italia, Milano, Egea, 2007.</p>
OTHER SCIENTIFIC /PROFESSIONAL ACTIVITIES	
Membership in the editorial board of Italian and International journals	<p>Editor in Chief, Global & Regional HTA.</p> <p>(past) Member of the Board of Pharmacoeconomics, Italian Research Articles and Global & Regional HTA.</p> <p>Referee for many journals, including Value in Health, Health Policy and Pharmacoeconomics.</p> <p>(past) Editor in Chief of the Journal "Economia e Politica del Farmaco".</p>
Membership in Professional / Scientific Committees	<p>(past) President of AIES (Associazione Italiana di Economia Sanitaria – Italian Association of Health Economics)</p> <p>Member of ISPOR (International Society for Pharmacoeconomics and Outcome Research)</p> <p>Member of iHEA (International Health Economics Association) and EUHEA (European Health Economics Association) (through Cergas)</p> <p>Member of the Scientific Board of the Bioindustry Park, Canavese, Italy</p>

	<p>Member of Scientific Committee of AIES Annual Conference (2004, 2009, 2010)</p> <p>Member of the Scientific Committee of AIES Conference "Economia del farmaco e delle tecnologie sanitarie" (last eight editions)</p> <p>Member of the National Committee by the Consiglio Superiore di Sanità "Economic impact of NIPT – Non-invasive prenatal test – in the Italian National Health Service"</p> <p>(past) Advisor - Aifa (Agenzia Italiana del Farmaco) (drugs price and reimbursement)</p>
--	--

<p>Main recent international conferences (since 2014)</p>	<p>EUHEA Conference 2018, Maastricht, 11-14 July 2018 Competition and efficiency in public procurement: a study on the Italian pharmaceutical market (with Armeni P, Bertolani A, Costa F, Otto M)</p> <p>ISPOR, 20th Annual European Congress, Glasgow 4-8 November 2017 Forecasting Pharmaceutical Expenditure in Europe: Is It Sustainable? (with Ferrandiz JM, Davis T, Kanavos P) Changing the Health Technology Assessment Paradigm for Combination Therapies (with RatcliffeM, Walker A, Edoos H, Caro JJ)</p> <p>HTAi, Annual Conference Meeting, Rome 17-21, June 2017 Unlocking the Potential of Established Products: Need for Incentives (with Nayroles G, Frybourg S, Gabriel S, et al)</p> <p>EUHEA Conference 2016, Hamburg, 13-16 July 2017 Direct and mediated impacts of pharmaceutical policies on firms' performance (with Armeni P, Costa F, Otto M)</p> <p>IHEA Conference 2015, Milan 12-15 July 2015 The Simultaneous Effects Of Pharmaceutical Policies From Payers' And Patients' Perspectives. Italy As A Case Study</p> <p>ISPOR, 20th Annual European Congress, 8-12 November 2014 Market Access for Medical Devices: Adapting to Change (with Charter R, Bottegoni G, Pistacchio L, et al)</p>
<p>Other conferences and international / national professional activities</p>	<p>Participation in many national conferences (including AIES Conferences) and ECM Workshops</p> <p>Member of international and national Advisory Boards for Pharmaceutical Companies (Health Economics and Market Access issues)</p>

Milan, May 2019


(Claudio Jommi)